Earnings Call Insights: Vivos Therapeutics (VVOS) Q4 2025
Management View
“2025 was a pivotal year for Vivos,” said (Co-Founder, Chairman of the Board & CEO R. Kirk Huntsman), adding that the company “proved our core thesis around patient demand and preference for our Vivos method” and said the SCN
Seeking Alpha’s Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
